Plus: new FDA approval for dapagliflozin; more
Tuesday, May 4, 2021 : Issue #1129 |
|
Letter from the Editor
Laura Martínez López, PharmD. Candidate 2021, LECOM, College of Pharmacy, presented us with a feature that looks at the benefits of GLP-1 agonists and SGLT-2 inhibitors in decreasing coronary health disease in patients with type 2 diabetes. The results with either product were very positive. So how do you make a choice? A1c and weight may be a deciding factor, as will the use of insulin. However, there may be one good reason to chose SGLT-2 inhibitors, and that could be the effect these drugs have on patients with chronic kidney disease.
Check out Laura’s Laterpay article and the newsflash from our publisher Steve Freed.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
Newsflash: FDA Approves Dapagliflozin for Chronic Kidney Disease
The FDA has approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk for kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) at risk for disease progression. This new approval in chronic kidney disease was based on results of the DAPA-CKD trial that was stopped early in March 2020 due to the efficacy of the treatment. |
TOP STORIES - Diabetes News and Research |
|
| |
|
Why Salt Restrictions?
Personalized medicine may provide a better way of determining the ideal range for sodium consumption. |
| |
|
|
|
|
| | | | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
